Spero Therapeutics, Inc.
SPRO
Price:
$0.9252
Market Cap:
$50.44M
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. t...[Read more]
Industry
Biotechnology
IPO Date
2017-11-02
Stock Exchange
NASDAQ
Ticker
SPRO
PE Ratio
[11.57]
ROE
[3.36%]
Current Ratio
[2.68]
Dividend Yield
[0%]
Enterprise Value
[-21227761.00]
Dividend History
The ROE as of December 2024 (TTM) for Spero Therapeutics, Inc. (SPRO) is 3.36%
According to Spero Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 3.36%. This represents a change of -192.55% compared to the average of -3.63% of the last 4 quarters.
Spero Therapeutics, Inc. (SPRO) Historical ROE (quarterly & annually)
How has SPRO ROE performed in the past?
The mean historical ROE of Spero Therapeutics, Inc. over the last ten years is -645.14%. The current 3.36% ROE has changed -100.52% with respect to the historical average. Over the past ten years (40 quarters), SPRO's ROE was at its highest in in the December 2023 quarter at 47.89%. The ROE was at its lowest in in the June 2022 quarter at -79.84%.
Average
-645.14%
Median
-63.25%
Minimum
-5180.61%
Maximum
21.34%
Spero Therapeutics, Inc. (SPRO) ROE by Quarter and Year
Discovering the peaks and valleys of Spero Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 124.39%
Maximum Annual ROE = 21.34%
Minimum Annual Increase = -133.73%
Minimum Annual ROE = -5180.61%
| Year | ROE | Change |
|---|---|---|
| 2023 | 21.34% | -133.73% |
| 2022 | -63.25% | -38.84% |
| 2021 | -103.41% | 76.14% |
| 2020 | -58.71% | -27.24% |
| 2019 | -80.69% | 124.39% |
| 2018 | -35.96% | -33.72% |
| 2017 | -54.26% | -78.35% |
| 2016 | -250.67% | -95.16% |
Spero Therapeutics, Inc. (SPRO) Average ROE
How has SPRO ROE performed in the past?
The current ROE of Spero Therapeutics, Inc. (SPRO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-48.44%
5-year avg
-56.95%
10-year avg
-645.14%
Spero Therapeutics, Inc. (SPRO) ROE vs. Peers
How is SPRO’s ROE compared to its peers?
Spero Therapeutics, Inc.’s ROE is greater than Assembly Biosciences, Inc. (-121.46%), greater than Achilles Therapeutics plc (-54.57%), greater than Instil Bio, Inc. (-37.44%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than NextCure, Inc. (-62.50%), greater than Nuvation Bio Inc. (-108.68%),
| Company | ROE | Market cap |
|---|---|---|
| -121.46% | $95.66M | |
| -54.57% | $40.33M | |
| -37.44% | $135.80M | |
| -8.54% | $8.20M | |
| -41.34% | $84.91M | |
| -62.50% | $26.11M | |
| -108.68% | $898.63M |
Build a custom stock screener for Spero Therapeutics, Inc. (SPRO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spero Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Spero Therapeutics, Inc. (SPRO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Spero Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Spero Therapeutics, Inc.'s ROE?
How is the ROE calculated for Spero Therapeutics, Inc. (SPRO)?
What is the highest ROE for Spero Therapeutics, Inc. (SPRO)?
What is the 3-year average ROE for Spero Therapeutics, Inc. (SPRO)?
What is the 5-year average ROE for Spero Therapeutics, Inc. (SPRO)?
How does the current ROE for Spero Therapeutics, Inc. (SPRO) compare to its historical average?